関連する実験動画
Updated: Jun 26, 2026

05:41
Non-invasive Assessment of Microvascular and Endothelial Function
Published on: January 29, 2013
アルファアドレナジック刺激が,地域収縮機能と心筋動脈の血流に与える影響,イシュケミアの有無にかかわらず
M I Miyamoto1, H A Rockman, B D Guth
1Seaweed Canyon Laboratory, Department of Medicine, University of California San Diego School of Medicine, La Jolla.
Circulation
|October 11, 1991
まとめ
イシュケミア中のアルファ・アドレナージック受容体刺激は,犬の地域収縮機能を低下させた. これは,内層への血流が維持されているにもかかわらず,心臓の外壁の血管収縮が原因で発生しました.
科学分野:
- 心血管生理学 心血管の生理学
- アドレナゲン受容体の薬理学 アドレナゲン受容体の薬理学
- 心筋力衰弱症の研究について
背景:
- アルファアドレネルゲン受容体活性化が心筋機能と血流に与える影響については,依然として議論されている.
- 以前の研究では,アルファアドレナージック刺激の効果に関する議論の余地のある結果が得られた.
研究 の 目的:
- 選択的なアルファ1およびアルファ2アドレナゲン受容体刺激が地域収縮機能に及ぼす影響を調査する.
- これらの刺激が正常および不血症の条件下におけるトランスムラル心筋血流分布に与える影響を評価する.
主な方法:
- 15匹の麻酔されたオープンチェスト犬が使用されました.
- 選択性アルファ1 (メトキサミン) とアルファ2 (BHT 933) アゴニストを左側環動脈冠動脈に注入した.
- 実験は,コントロール状態と誘発性不血症状態の両方で,恒常的な冠動脈 perfusion 圧力で実施されました.
主要な成果:
- アルファ・アドレナージック刺激は,正常な条件下では収縮機能を変化させなかった.
- 缺血の間,アルファ1とアルファ2の両方の刺激により,地域収縮機能 (%WT) が著しく低下しました.
- 両方の受容体刺激は,コントロール中にトランスムラル血流の均等な減少をもたらしたが,イシュケミア中にサブピカード/サブエンドカーディアルの血流が変化し,比率が増加した.
結論:
- 精選的なアルファ1またはアルファ2受容体媒介の血管収縮は,イシュケミア中の心臓の外壁の層で,地域収縮機能を低下させます.
- これは,心下血流が変化せず,心下血流と心下血流の比率が改善した状態でも起こります.
- この犬のモデルでは,アルファ-アドレナージ的血管収縮が,心筋不全の際に悪影響を及ぼしているようです.
関連する概念動画
Anatomy of the Heart
The human heart is made up of three layers of tissue that are surrounded by the pericardium, a membrane that protects and confines the heart. The outermost layer, closest to the pericardium, is the epicardium. The pericardial cavity separates the pericardium from the epicardium. Beneath the epicardium is the myocardium, the middle layer, and the endocardium, the innermost layer. There are four chambers of the heart: the right atrium, the right ventricle, the left atrium, and the left ventricle.
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Autoregulation of Blood Flow
Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation.
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

